Search results
Author(s):
Robert Mentz
Added:
1 year ago
ESC 2023 — Dr Robert Mentz (Duke University Medical Center, US) joins us to provide a succinct summary of the findings and key take-home messages from the HEART-FID study (NCT03037931).
HEART-FID(American Regent, Inc.) aimed to determine the safety and efficacy of iron therapy using intravenous (IV) ferric carboxymaltose (FCM) as compared to a placebo in the treatment of patients with heart…
View more
Remnant Lipoproteins and ASCVD
Author(s):
Mohanad Gabani
,
Michael D Shapiro
,
Peter P Toth
Added:
1 year ago
Article
Author(s):
Steven E Nissen
,
Maryam Barkhordarian
Added:
1 year ago
AHA 2023 — Investigator, Dr Steven E Nissen (Cleveland Clinic, US) is interviewed by CardioNerds Medical Education Fellow, Dr Maryam Barkhordarian (HMH Palisades Medical Center, US) on the trial that assessed the efficacy and safety of lepodisiran, a small interfering RNA (NCT05565742).The main purpose of this phase 2, randomised, double-blind, placebo-controlled study (Eli Lilly and Company) is…
View more
Author(s):
Steven E Nissen
Added:
2 months ago
ACC 2025 - 540-day follow up of lepodisiran in patients with elevated lipoprotein(a) (Lp(A)) shows the extended duration of action of lepodisiran will allow infrequent dosing in the ongoing cardiovascular outcome trial.Dr Steven Nissen (Cleveland Clinic, Cleveland, US) joins us onsite at ACC to discuss the ALPACA phase 2 trial (NCT05565742), investigating the safety and efficacy of lepodisiran,…
View more
Author(s):
Michelle O'Donoghue
Added:
1 year ago
ESC 23 — Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) outlines a trial update from OCEAN(a)-Dose Extension trial (NCT05581303) in this succinct interview.
OCEAN(a)-DOSE (Amgen) was a dose-finding study aiming to evaluate a siRNA, olpasiran, and its effect on risk for coronary heart disease death, myocardial infarction or urgent coronary revascularization when administered…
View more
Added:
1 year ago
Source:
Radcliffe Cardiology
AUTHOR: Brad WilsonIn a study published in the Journal of the American College of Cardiology (JACC), Dr Elias Björnson and his colleagues demonstrated that lipoprotein(a) (Lp(a)) is approximately six times more atherogenic than low-density lipoprotein (LDL) per particle.Lp(a) is a lipoprotein particle that has long been recognised as a causal factor for coronary heart disease (CHD). However,…
View more
Piotr Ponikowski
Research Area(s) / Expertise:
Job title: Head of the Department of Heart Diseases
Author
Author(s):
Nicolas M Van Mieghem
,
Joost Daemen
Added:
1 year ago
What is hot at ESC 2023?
In this episode of View of the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, NL) preview the hot line and late-breaking data presented at ESC Congress 2023.
With their dynamic analysis, they place these highly anticipated trials within a context, highlighting the real-world implications tied to the data releases.
Top trials…
View more
Author(s):
Rishi Rikhi
,
Michael D Shapiro
Added:
1 year ago